Immediate Impact
1 from Science/Nature 56 standout
Citing Papers
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy
2024 Standout
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2023 Standout
Works of O. Kardaun being referenced
Toward individual prognosis of IgA nephropathy
1986
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| O. Kardaun | 581 | 321 | 209 | 39 | 790 | |
| W. Lotz | 693 | 183 | 191 | 39 | 899 | |
| T.E. Evans | 535 | 243 | 137 | 41 | 717 | |
| T. Koskela | 617 | 259 | 197 | 39 | 732 | |
| D. C. McDonald | 860 | 435 | 271 | 72 | 942 | |
| Chris Walker | 520 | 351 | 129 | 55 | 849 | |
| K.-D. Zastrow | 607 | 249 | 135 | 45 | 696 | |
| Mathias Brix | 853 | 424 | 240 | 67 | 921 | |
| A. Olszewski | 444 | 21 | 11 | 70 | 846 | |
| I. Coffey | 610 | 423 | 165 | 57 | 738 | |
| Mark S. Robbins | 65 | 23 | 100 | 43 | 810 |
All Works
Loading papers...